Creative Medical Technology Completes Patient Enrollment In FDA-Cleared ADAPT Clinical Trial For CELZ-201

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the successful completion of patient enrollment in its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company's proprietary perinatal tissue-derived cell therapy for the treatment of chronic lower back pain associated with degenerative disc disease.

Enrollment completion follows a previously announced positive independent Data Safety Monitoring Board (DSMB) safety review, which confirmed that CELZ-201 demonstrated a favorable safety profile with no significant adverse events and supported continued advancement of the trial.

With enrollment now complete, CELZ has reached a critical execution milestone, transitioning the ADAPT program into its next phase focused on follow-up, and data analysis. Company leadership, investigators, and clinical partners expressed strong enthusiasm as CELZ advances toward what management believes could represent a paradigm shift in the treatment of chronic back pain, a condition impacting more than 16 million Americans and representing a multi-billion-dollar market with limited durable, non-surgical solutions.